- Location
Relvar Ellipta
"-
GSK Have Received Marketing Authorization From The European Commission for Relvar Ellipta
Nov 20, 2013GlaxoSmithKline (GSK) and Theravance have received marketing authorization from the European Commission (EC) for their jointly-developed asthma and chronic obstructive pulmonary disease (COPD) drug 'Relvar Ellipta'. Relvar, which is a ...
Tags: GSK, Relvar Ellipta
-
GSK and Theravance Reaveals The Availability of Breo Ellipta
Nov 4, 2013UK-based GlaxoSmithKline (GSK) and US-based Theravance have announced the availability of BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), in the US pharmacies. BREO ELLIPTA is a ...
-
Theravance Announced That The EMA Has Recommended Marketing Approval
Sep 20, 2013GlaxoSmithKline and biopharmaceutical company Theravance have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for fluticasone furoate/vilanterol ...
-
GSK and Theravance Have Withdrawn License Application for FF and VI
Jul 16, 2013GlaxoSmithKline (GSK) and Theravance have withdrawn license application for the use of inhaled drug fluticasone furoate (FF) and vilanterol (VI), with proposed brand name of Relvar Ellipta, as treatment for chronic obstructive pulmonary ...
Tags: Japan, GSK, Relvar License